An Evaluation Model for Biotechnology which Patent Strength is considerated─Protein Expression System as a Case Study

• Main Authors: TSUI-MIN CHEN, 陳翠敏
• Other Authors: LAI YI-XUAN
• Format: Others
• Language: zh-TW
• Published: 2011
• Online Access: http://ndltd.ncl.edu.tw/handle/95044857222268955113

碩士 === 中華大學 === 科技管理學系碩士班 === 99 === Over the last few decades, the Biotechnology industry has become a major development project in many counties around the world. This industry is a knowledge-intensived and knowledge-based industry. In addition, the main value of its research and innovation is from the company's intangible assets. Generally, In the biotech industry, it can be believed that the biotech industry is more mature and successful field to the marketing. However, technology is often not made it works. Due to its pharmaceutical products terminal technology, the use of general financial low price model and only biotech market value estimated directly estimate the value of its technology. In fact, this industry is having a risk: lacking practical considerations. Due to it can not be provided reference such as the biotech industry in the pharmaceutical industry as an important reference for the same time, both because the technology for the value of the transaction there is a considerable knowledge gap and can not intersect. In the urgent needs how to calculate the objective end-born African biotech industry, the technical value of pharmaceutical products and mke the technology valuation results are close to the practical side for these biotech companies. In particular, all categories of intangible assets are more often discussed in the patent, mainly because of the patent not only contains technical ideas, more importantly, legally conferred by the patent's "exclusive right", this feature allows patent rights in literature did not contain disclosure than other, more technical thinking, analysis has become even predict the development of various technologies as a tool. This research is in the biopharmaceutical industry and "protein expression system" technology, for example, on behalf of its core technology patent, the combination of patent strength evaluation and to explore the biotech commercialization of technology from research to the real existence of the process various risk factors, and thus the field of construction technology was born biotech valuation model. This study establishes a biotech valuation model of medical technology, the Department has considered the development of technology from the beginning to the final stage of the commercialization of the market can really make a profit in the process will encounter a variety of risk factors at the same time, taking into consideration when companies When a patent for this technology, using patented "exclusive rights" exclude competitors, competition, thereby enabling enterprises to maintain the competitive advantage of profitable, mainly for technology that is consistent with the actual business transaction's main criterion for the technology to provide a reasonable The technical value. The propose of biotech valuation model techniques can be used as strategic management tool for business managers, and to provide patent licenses, technology transactions and corporate mergers and acquisitions, the value of reference. At the same time, not only technology or patent owner the value of their technology for more concepts, the technology buyers can also provide a reasonable value of technical assessment, not only included academic value, but also with industrial value in use.